Number 11

We don’t have to be a year behind

Editorial 1 March 2006 0

Late last year, US patients with advanced renal cell cancer gained access to an oral multi-kinase inhibitor, Nexavar (sorafinib) – the first new drug approved for this disease in the last 10 years. Manufacturer Bayer [more]

... [ more ]

Lesley Fallowfield: getting the message across

Cover Story 1 March 2006 0

It was while studying the benefits of offering patients a choice between radical and breast conserving therapy that Lesley Fallowfield first demonstrated the importance of doctor patient communication. Her findings haven’t always been welcome, but [more]

... [ more ]

Beyond the Herceptin hype…

Drug Watch 1 March 2006 0

Herceptin may turn out to be the biggest advance in treating breast cancer since tamoxifen. But if we are to prevent soaring drugs bills eating up our health budgets or barring Europe’s poorer patients from [more]

... [ more ]

Phase III trials in oncology

Senza categoria 1 March 2006 0

Survival data from phase III trials can be very misleading because patients are not offered the best follow-up therapy argue Siegfried Seeber and Ada Braun in CancerWorld’s new Forum section. Emma Mason canvassed clinical trial [more]

... [ more ]

Mr Hodgkin’s disease

Senza categoria 1 March 2006 0

Volker Diehl cultured the cells that characterise Hodgkin’s disease when everyone else had failed. He has high hopes that molecular medicine will throw light on many questions that remain unanswered. But he stresses that it [more]

... [ more ]

Is radical prostatectomy of benefit in men with localised prostate cancer?

Impact Factor 1 March 2006 0

In men with intermediate- to high-risk prostate cancer, radical prostatectomy has been shown to lower the risk of local or systemic progression, and cancer-specific and overall mortality, compared with watchful waiting. Download full article

... [ more ]

NEWSROUND

Senza categoria 1 March 2006 0

Selected press reports complied by the ESO Cancer Media Centre Download full article

... [ more ]

When clinical trials are compromised

Patient Voice 1 March 2006 0

Advocates for early access to unproven treatments may believe they are helping patients, but their actions can put current patients at risk and deny future patients the knowledge they need to make evidence-based treatment decisions, [more]

... [ more ]

A trial of strength

Senza categoria 1 March 2006 0

Patients, doctors, academic researchers and the World Health Organization all want industry to be a lot more open about the drugs they are trialling. The industry is pleading commercial confidentiality. The two sides are locked [more]

... [ more ]